Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 19/20 | 0.49 |
| ▸ | FPR3 | P25089 | 1/20 | 0.47 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7000018 | 0.90 | CCR1 (0.53) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL6997000 | 0.89 | CCR1 (0.49) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL7001038 | 0.86 | MEN1 (0.45) | CCR1FPR3GPR65GPR35MEN1 | |
| SCHEMBL6993640 | 0.86 | CCR1 (0.59) | CCR1FPR3GPR65GPR35MEN1 | |
| SCHEMBL6993588 | 0.85 | CCR1 (0.48) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL7002872 | 0.84 | CCR1 (0.51) | CCR1FPR3GPR65GPR35MEN1 | |
| SCHEMBL7000591 | 0.84 | CCR1 (0.62) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL7002694 | 0.82 | FAAH (0.49) | CCR1FPR3GPR65GPR35KMT2A | |
| SCHEMBL7144980 | 0.80 | CCR1 (0.61) | CCR1FPR3GPR65GPR35 | |
| SCHEMBL7002150 | 0.80 | CCR1 (0.51) | CCR1FPR3GPR65GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326867-A2 | BRIDGED PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020119961-A1 | Bridged piperazine derivatives | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002032901-A2 | BRIDGED PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119961-A1 | Bridged piperazine derivatives | MYD88, IL4, ARG1 | CCR1 7/4885FPR3 348/4885GPR65 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.